Elvia Cowan - 16 Jul 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
16 Jul 2024
Net transactions value
-$295,400
Form type
4
Filing time
17 Jul 2024, 16:03:15 UTC
Previous filing
09 Jul 2024
Next filing
05 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $129,600 +5,000 +39% $25.92 17,723 16 Jul 2024 Direct
transaction PCVX Common Stock Sale $425,000 -5,000 -28% $85.00 12,723 16 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5,000 -4% $0.000000 119,000 16 Jul 2024 Common Stock 5,000 $25.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.
F2 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.